HC Wainwright & Co. Reiterates Buy on scPharmaceuticals, Maintains $18 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao has reiterated a 'Buy' rating on scPharmaceuticals (NASDAQ:SCPH) and maintained a price target of $18.
July 19, 2023 | 10:04 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
scPharmaceuticals (NASDAQ:SCPH) has been reiterated with a 'Buy' rating by HC Wainwright & Co. The price target remains at $18.
The reiteration of a 'Buy' rating by a reputable analyst like Douglas Tsao from HC Wainwright & Co. is a positive signal for scPharmaceuticals. The maintained price target of $18 also indicates the analyst's confidence in the company's potential. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100